Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy MorphoSys AG ADR stock

Learn how to easily invest in MorphoSys AG ADR stock.

MorphoSys AG ADR is a biotechnology business based in the US. MorphoSys AG ADR shares (MOR) are listed on the NASDAQ and all prices are listed in US Dollars. MorphoSys AG ADR employs 648 staff and has a trailing 12-month revenue of around $195.1 million.

How to buy shares in MorphoSys AG ADR

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MOR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

MorphoSys AG ADR stock price (NASDAQ: MOR)

Use our graph to track the performance of MOR stocks over time.

MorphoSys AG ADR shares at a glance

Information last updated 2022-09-18.
Latest market close$4.46
52-week range$4.07 - $12.61
50-day moving average $5.22
200-day moving average $6.45
Wall St. target price$13.45
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-4.61

Buy MorphoSys AG ADR shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Stocks, Options, ETFs
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MorphoSys AG ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MorphoSys AG ADR price performance over time

Historical closes compared with the close of $4.46 from 2022-09-23

1 week (2022-09-16) -14.56%
1 month (2022-08-25) -5.11%
3 months (2022-06-24) -9.90%
6 months (2022-03-24) -38.65%
1 year (2021-09-24) -63.38%
2 years (2020-09-25) -85.90%
3 years (2019-09-25) 27.99
5 years (2017-09-21) N/A

MorphoSys AG ADR financials

Revenue TTM $195.1 million
Gross profit TTM $147.4 million
Return on assets TTM -8.47%
Return on equity TTM -296.68%
Profit margin 0%
Book value $1.04
Market capitalisation $698.3 million

TTM: trailing 12 months

MorphoSys AG ADR share dividends

We're not expecting MorphoSys AG ADR to pay a dividend over the next 12 months.

MorphoSys AG ADR share price volatility

Over the last 12 months, MorphoSys AG ADR's shares have ranged in value from as little as $4.07 up to $12.61. A popular way to gauge a stock's volatility is its "beta".

MOR.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MorphoSys AG ADR's is 0.975. This would suggest that MorphoSys AG ADR's shares are less volatile than average (for this exchange).

MorphoSys AG ADR overview

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Frequently asked questions

What percentage of MorphoSys AG ADR is owned by institutions?
Currently 2.075% of MorphoSys AG ADR shares are held by institutions.
How many people work for MorphoSys AG ADR?
Latest data suggests 648 work at MorphoSys AG ADR.
When does the fiscal year end for MorphoSys AG ADR?
MorphoSys AG ADR's fiscal year ends in December.
Where is MorphoSys AG ADR based?
MorphoSys AG ADR's address is: Semmelweisstrasse 7, Planegg, Germany, 82152
What is MorphoSys AG ADR's ISIN number?
MorphoSys AG ADR's international securities identification number is: US6177602025
What is MorphoSys AG ADR's CUSIP number?
MorphoSys AG ADR's Committee on Uniform Securities Identification Procedures number is: 617760202

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site